In a randomized trial of 106 adolescents and young adults with hereditary cancer predisposition, adding AYA-RISE to a clinic visit improved knowledge of cancer risk before age 30 compared with a clinic visit alone. Researchers observed no increase in distress, but the main analyses did not establish additional benefits for lifetime-risk or screening knowledge.